XML 15 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Net income $ 16,878 $ 2,070
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 1,910 2,027
Net (accretion) amortization of (discounts) premiums on securities (962) 718
Provision (benefit) for credit losses 2,928 (5,456)
Share-based compensation 506 569
Deferred income tax expense 483 3,761
Proceeds from sale of loans held for sale 6,888 5,853
Originations of loans held for sale (4,878) (4,899)
Income on company owned life insurance (2,777) (1,298)
Net gain on sale of loans held for sale (117) (88)
Net loss on sale of other assets 0 13
Decrease (increase) in other assets 10,982 (6,240)
(Decrease) increase in other liabilities (21,836) 15,260
Net cash provided by operating activities 10,005 12,290
Cash flows from investing activities:    
Purchases of available for sale securities (15,879) (64,613)
Purchases of held to maturity securities (1,235) (406)
Proceeds from principal payments, maturities and calls on available for sale securities 15,965 18,298
Proceeds from principal payments, maturities and calls on held to maturity securities 4,104 4,783
Net (increase) decrease in loans (76,443) 16,972
Purchase of company owned life insurance (72,984) (24)
Purchases of premises and equipment (816) (1,174)
Net cash used in investing activities (147,288) (26,164)
Cash flows from financing activities:    
Net increase in deposits 268,179 183,845
Net decrease in short-term borrowings (44,000) (52,000)
Purchases of common stock for treasury (481) (393)
Cash dividends paid to common and preferred shareholders (6,384) (4,982)
Net cash provided by financing activities 217,314 126,470
Net increase in cash and cash equivalents 80,031 112,596
Cash and cash equivalents, beginning of period 87,321 124,442
Cash and cash equivalents, end of period $ 167,352 $ 237,038